Table 1.
Baseline patient characteristics
| Characteristics | KN046 3 mg/kg Q2W + nab-paclitaxel (n = 16) | KN046 5 mg/kg Q2W + nab-paclitaxel (n = 11) | Total (n = 27) |
|---|---|---|---|
| Age, median (range) 1 | 53.5 (35–70) | 45 (33–62) | 50 (33–70) |
| ECOG PS | |||
| 0 | 9 (56.3%) | 5 (45.5%) | 14 (51.9%) |
| 1 | 7 (43.8%) | 6 (54.5%) | 13 (48.1%) |
| Grade | |||
| 1 | 0 | 0 | 0 |
| 2 | 4 (25.0%) | 2 (18.2%) | 6 (22.2%) |
| 3 | 7 (43.8%) | 6 (54.5%) | 13 (48.1%) |
| UNK | 5 (31.3%) | 3 (27.3%) | 8 (29.6%) |
| Stage (cTNM) | |||
| IIIa | 1 (6.3%) | 0 | 1 (3.7%) |
| IIIb | 0 | 1 (9.1%) | 1 (3.7%) |
| IIIc | 2 (12.5%) | 0 | 2 (7.4%) |
| IV | 13 (81.25%) | 10 (90.9%) | 23 (85.2%) |
| Distant metastasis | |||
| Yes | 14 (87.5%) | 9 (81.8%) | 23 (85.2%) |
| No | 2 (12.5%) | 2 (18.2%) | 4 (14.8%) |
| Number of disease sites | |||
| 0–3 | 3 (18.8%) | 3 (27.3%) | 6 (22.2%) |
| ≥4 | 13 (81.3%) | 8 (72.7%) | 21 (77.8%) |
| Metastatic site | |||
| Lymph nodes | 10 (62.5%) | 6 (54.5%) | 16 (59.3%) |
| Lung | 7 (43.8%) | 6 (54.5%) | 13 (48.1%) |
| Liver | 5 (31.3%) | 1 (9.1%) | 6 (22.2%) |
| Brain | 1 (6.3%) | 1 (9.1%) | 2 (7.4%) |
| Bone | 5 (31.3%) | 4 (36.4%) | 9 (33.3%) |
| PD-L1 status | |||
| <1% | 7 (43.8%) | 8 (72.7%) | 15 (55.6%) |
| ≥1% | 6 (37.5%) | 3 (27.3%) | 9 (33.3%) |
| UNK | 3 (18.8%) | 0 | 3 (11.1%) |
Data are presented as n (%).
ECOG PS Eastern Cooperative Oncology Group performance status, UNK unknown, PD-L1 programmed death-ligand 1.